Skip to main content
Fig. 3 | Journal for ImmunoTherapy of Cancer

Fig. 3

From: Immunoglobulin somatic hypermutation has clinical impact in DLBCL and potential implications for immune checkpoint blockade and neoantigen-based immunotherapies

Fig. 3

Comparison of PD-1 expression between groups. a A representative image of a DLBCL sample is from an ABC-DLBCL case with a low degree of IGHV SHM (2.94%) and a long (21 amino acids) heavy chain complementarity determining region 3 (HCDR3). Fluorescence multiplex immunohistochemistry detected that PD-1 was expressed in T cells and proximal to PD-L1-expressing B cells. b Long HCDR3 length was associated with high PD-L1 expression in B cells in GCB-DLBCL and high PD-1 expression in CD4+/CD8+ T cells in ABC-DLBCL. c In the training set, a high degree of IGHV SHM (SHMhi) was associated with low PD-1 expression in CD8+/CD4+ T cells and B cells in ABC-DLBCL. In the validation set, IGHV SHMhi was associated with lower PD-L1 expression in CD8+ T cells. d PD-L2 protein expression in B cells was associated with a high degree of IGHV SHM. PD-L1 gene amplification was associated with a significantly higher mean degree of SHM in the IGHV diagnostic sequence. PD-L1/L2 gene amplification was associated with a higher mean percentage of subclones with IGHV ongoing SHM in the sequence repertoire

Back to article page